Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epstein-Barr virus vaccine - GlaxoSmithKline/MedImmune Vaccines

Next Previous
Drug Profile

Epstein-Barr virus vaccine - GlaxoSmithKline/MedImmune Vaccines

Alternative Names: 268664; EBV gp350 - Henogen; EBV vaccine 268664 - GlaxoSmithKline; GSK Biologicals' EBV vaccine (268664); GSK-268664; HENO 4; Recombinant gp350 vaccine for infectious mononucleosis - GlaxoSmithKline

Latest Information Update: 18 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune Vaccines
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epstein-Barr virus infections; Infectious mononucleosis; Post-transplant lymphoproliferative disorder

Most Recent Events

  • 20 Apr 2011 Epstein-Barr virus vaccine is still in phase II development
  • 06 Jul 2009 Henogen has been acquired by Novasep
  • 27 May 2009 EBV vaccine is still in phase II development trials for Epstein-Barr virus infections in Belgium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top